FOXO3 and cancer: This screen identified UCN‐01, 7‐hydroxystaurosporine, as a potential candidate in terms of its abilities to inhibit FoxO3 phosphorylation and translocation and supported by the fact that this agent is approved for phase II anti‐cancer clinical trials (http://clinicaltrials.gov).